Drilldown: Medicines

Butorphanol (1) · Codeine (2) · Dextropropoxyphene (1) · Dihydrocodeine (1) · Ethylmorphine (1) · Etodolac (1) · Fentanyl (1) · Hydrocodone (1) · Hydromorphone (1) · Levorphanol (1) · Meperidine (1) · Nabumetone (1) · Nalbuphine (1) · Oxymorphone (1) · Papaverine (1) · Pentazocine (1) · Tapentadol (1)

None (5) · (multiple, generic dominant) (1) · Darvon (1) · Demerol (1) · Dilaudid (1) · Duragesic (1) · Lodine (US brand discontinued); generic (1) · Nubain (1) · Nucynta (1) · Opana (1) · Relafen (1) · Stadol (1) · Talwin (1) · Vicodin (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antiparkinsonian · Antipsychotic · Empathogen · Neuroleptic · Cathinone

Other values:

Search

Kappa agonist; mu antagonist (1) · Kappa agonist; mu partial agonist (1) · Kappa agonist; mu partial agonist/antagonist (1) · Mu-opioid agonist; norepinephrine reuptake inhibitor (1) · Mu-opioid receptor agonist (4) · Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Mu-opioid receptor agonist; sodium channel blocker (1) · Mu/kappa/delta agonist; NMDA antagonist (1) · Phosphodiesterase inhibitor; calcium channel blocker (1) · Potent mu-opioid receptor agonist (3) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) · '"`UNIQ--vote-000011F4-QINU`"' Like all NSAIDs, raises CV thrombotic risk modestly (FDA 2014/2015 advisory) and produces GI, renal, hypertensive, and platelet-inhibitory effects characteristic of the class'"`UNIQ--ref-000011F5-QINU`"'. (1) · '"`UNIQ--vote-00001269-QINU`"' Renal, GI, hypertensive, and CV effects parallel the class profile; modest COX-2 preference may underlie some literature suggesting slightly better GI tolerability than non-selective NSAIDs, though clinically the difference is small'"`UNIQ--ref-0000126A-QINU`"'. (1)

None (15) · Mild to moderate pain; cough suppression (low-dose). (1) · '"`UNIQ--vote-000011F6-QINU`"', '"`UNIQ--vote-000011F7-QINU`"', '"`UNIQ--vote-000011F8-QINU`"' (1) · '"`UNIQ--vote-0000126B-QINU`"', '"`UNIQ--vote-0000126C-QINU`"', '"`UNIQ--vote-0000126D-QINU`"' (1)

None (15) · 1000 mg PO once daily; 500-2000 mg/d in single or divided doses (1) · Adult: 15–60 mg every 4 hours as needed. (1) · IR 200-400 mg PO every 6-8 hours; ER 400-1000 mg PO once daily (1)

None (15) · 200, 300, 400, 500 mg IR tablets/capsules; 400, 500, 600 mg ER tablets (1) · 500, 750 mg tablets (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (15) · 1000 mg/d (osteoarthritis); 1200 mg/d (rheumatoid arthritis) (1) · 2000 mg/d (1) · 360 mg/day (1)

None (15) · Oral (2) · PO (only formulation marketed in the US). (1)

None (15) · 30–60 min (PO) (1) · Analgesia within 30 minutes; full anti-inflammatory effect over days (1) · Analgesia within hours; anti-inflammatory effect over days (1)

None (15) · 24 hours (1) · 4–6 hours (1) · 6-8 hours (IR); 24 hours (ER) (1)

None (15) · 2.5–3 hours (1) · ~24 hours (6-methoxy-2-naphthylacetic acid, the active metabolite)'"`UNIQ--ref-000011F9-QINU`"' (1) · ~7 hours'"`UNIQ--ref-0000126E-QINU`"' (1)

None (15) · ~100% (oral; absorption complete)'"`UNIQ--ref-0000126F-QINU`"' (1) · ~38% (oral; non-acidic prodrug improves GI tolerability over many other NSAIDs)'"`UNIQ--ref-000011FA-QINU`"' (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1)

None (15) · Avoid after 20 weeks (NSAID-class FDA 2020 advisory on fetal renal injury and oligohydramnios with second/third-trimester use).<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Avoid after 20 weeks (NSAID-class FDA 2020 advisory).<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1)

None (15) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · [[USLegal:Prescription only|Rx-only]] in US. Carries the NSAID-class '''Boxed Warning''' for cardiovascular thrombotic events and serious GI bleeding'"`UNIQ--ref-000011FB-QINU`"' (1) · [[USLegal:Prescription only|Rx-only]] in US. NSAID-class '''Boxed Warning''' for CV thrombotic events and GI bleeding'"`UNIQ--ref-00001270-QINU`"' (1)